Literature DB >> 34432293

Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication.

David Hui1, Allison De La Rosa1, Diana L Urbauer2, Thuc Nguyen1, Eduardo Bruera1.   

Abstract

BACKGROUND: Agitated delirium is common and highly distressing. Medications are often needed to reduce agitation, but it is unclear what the desired level of sedation is. This study assessed personalized sedation goals (PSGs) and their predictors for patients in a delirium clinical trial and in clinical vignettes.
METHODS: This was a preplanned secondary analysis of a double-blind randomized clinical trial examining the sedative effect of chlorpromazine and/or haloperidol in patients with agitated delirium. At the baseline, caregivers and nurses were independently asked to select the PSG for the trial patient from 5 choices corresponding to Richmond Agitation Sedation Scale (RASS) scores of 0 or higher (no sedation), -1 to -2, -3, -4, and -5 (deep sedation). Respondents also selected a PSG for 6 vignettes that differed by the level of agitation, ability to communicate, and survival.
RESULTS: Forty-two caregivers and 39 nurses answered questions regarding PSGs. For the trial patient, caregivers preferred RASS scores of -1 to -2 most often (36%), whereas nurses preferred an RASS score of -3 most often (51 %). Caregivers were significantly more likely than nurses to choose lighter sedation (odds ratio [OR], 4.8; P = .01) despite reporting greater delirium-related distress (P = .0006). Patients were undersedated 33% to 53% of the time and oversedated 0% to 15% of the time according to the PSG response criteria. In the case vignettes, deeper sedation was preferred by nurses (P < .0001) and for patients who were unable to communicate (OR, 3.1-4.4; P < .0001) and had a shorter life expectancy (OR, 1.7; P = .002).
CONCLUSIONS: Caregivers often preferred lighter sedation than nurses. Many patients were undersedated in comparison with caregivers' PSGs, and this highlights room for improvement. LAY
SUMMARY: In the last days of life, many patients with cancer develop delirium and become restless/agitated; this can be highly distressing. Caregivers and physicians alike are often concerned about the use of sedatives for agitated delirium and try to find a balance between maximizing comfort and maintaining communication. This study examined the concept of a personalized sedation goal for setting an individualized target for the level of sedation. Caregivers often preferred lighter sedation than nurses. Many patients were undersedated in comparison with caregivers' stated goals, and this highlights room for improvement.
© 2021 American Cancer Society.

Entities:  

Keywords:  antipsychotic agents; delirium; neoplasms; palliative care; pharmacologic therapy; randomized controlled trial

Mesh:

Substances:

Year:  2021        PMID: 34432293      PMCID: PMC8665008          DOI: 10.1002/cncr.33876

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.

Authors:  David Hui; Allison De La Rosa; Annie Wilson; Thuc Nguyen; Jimin Wu; Marvin Delgado-Guay; Ahsan Azhar; Joseph Arthur; Daniel Epner; Ali Haider; Maxine De La Cruz; Yvonne Heung; Kimberson Tanco; Shalini Dalal; Akhila Reddy; Janet Williams; Sapna Amin; Terri S Armstrong; William Breitbart; Eduardo Bruera
Journal:  Lancet Oncol       Date:  2020-05-29       Impact factor: 41.316

2.  Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review.

Authors:  Roozbeh Nikooie; Karin J Neufeld; Esther S Oh; Lisa M Wilson; Allen Zhang; Karen A Robinson; Dale M Needham
Journal:  Ann Intern Med       Date:  2019-09-03       Impact factor: 25.391

3.  The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.

Authors:  David Hui; Kenneth Hess; Seyedeh S Dibaj; Joseph Arthur; Rony Dev; Shalini Dalal; Suresh Reddy; Eduardo Bruera
Journal:  Cancer       Date:  2018-02-22       Impact factor: 6.860

4.  Goals of care and treatment in terminal delirium: A qualitative study of the views and experiences of healthcare professionals caring for patients with cancer.

Authors:  Megumi Uchida; Tatsuya Morita; Yoshinori Ito; Kazuko Koga; Tatsuo Akechi
Journal:  Palliat Support Care       Date:  2019-08

5.  Sedation for symptom control in Japan: the importance of intermittent use and communication with family members.

Authors:  T Morita; S Inoue; S Chihara
Journal:  J Pain Symptom Manage       Date:  1996-07       Impact factor: 3.612

6.  The central role of prognosis in clinical decision making.

Authors:  Thomas M Gill
Journal:  JAMA       Date:  2012-01-11       Impact factor: 56.272

7.  Family-perceived distress from delirium-related symptoms of terminally ill cancer patients.

Authors:  Tatsuya Morita; Kei Hirai; Yukihiro Sakaguchi; Satoru Tsuneto; Yasuo Shima
Journal:  Psychosomatics       Date:  2004 Mar-Apr       Impact factor: 2.386

8.  Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).

Authors:  E Wesley Ely; Brenda Truman; Ayumi Shintani; Jason W W Thomason; Arthur P Wheeler; Sharon Gordon; Joseph Francis; Theodore Speroff; Shiva Gautam; Richard Margolin; Curtis N Sessler; Robert S Dittus; Gordon R Bernard
Journal:  JAMA       Date:  2003-06-11       Impact factor: 56.272

Review 9.  The experiences of caregivers of patients with delirium, and their role in its management in palliative care settings: an integrative literature review.

Authors:  Anne M Finucane; Jean Lugton; Catriona Kennedy; Juliet A Spiller
Journal:  Psychooncology       Date:  2016-05-01       Impact factor: 3.894

View more
  1 in total

1.  Prognostication of the Last Days of Life.

Authors:  Masanori Mori; Tatsuya Morita; Eduardo Bruera; David Hui
Journal:  Cancer Res Treat       Date:  2022-03-30       Impact factor: 5.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.